New drug combo shows promise against Hard-to-Treat colorectal cancer
NCT ID NCT03926338
First seen Nov 20, 2025 · Last updated Jun 23, 2026 · Updated 24 times
Summary
This phase 2 trial is testing whether giving the immunotherapy drug toripalimab, alone or with the anti-inflammatory drug celecoxib, before surgery can improve outcomes for people with a specific type of colorectal cancer (dMMR/MSI-H). About 270 participants will receive the treatment for 12 weeks before surgery. The main goals are to see if the cancer disappears completely after treatment and to track how long patients remain cancer-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Sixth Affiliated Hospital of Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510655, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
toripalimab and celecoxib
What this could lead to
If successful, this could lead to a new treatment approach that shrinks tumors before surgery, potentially improving survival and reducing recurrence in patients with this specific colorectal cancer type.
What could go wrong
This is an early phase 2 trial with a moderate number of participants, so results may not apply to all patients. The combination therapy may cause side effects, and it is unclear if it will outperform standard treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.